Literature DB >> 26538284

Defining ATM-Independent Functions of the Mre11 Complex with a Novel Mouse Model.

Alessia Balestrini1, Laura Nicolas2, Katherine Yang-Lott3, Olga A Guryanova4, Ross L Levine4, Craig H Bassing3, Jayanta Chaudhuri2, John H J Petrini5.   

Abstract

UNLABELLED: The Mre11 complex (Mre11, Rad50, and Nbs1) occupies a central node of the DNA damage response (DDR) network and is required for ATM activation in response to DNA damage. Hypomorphic alleles of MRE11 and NBS1 confer embryonic lethality in ATM-deficient mice, indicating that the complex exerts ATM-independent functions that are essential when ATM is absent. To delineate those functions, a conditional ATM allele (ATM(flox)) was crossed to hypomorphic NBS1 mutants (Nbs1(ΔB/ΔB) mice). Nbs1(ΔB/ΔB) Atm(-/-) hematopoietic cells derived by crossing to vav(cre) were viable in vivo. Nbs1(ΔB/ΔB) Atm(-/-) (VAV) mice exhibited a pronounced defect in double-strand break repair and completely penetrant early onset lymphomagenesis. In addition to repair defects observed, fragile site instability was noted, indicating that the Mre11 complex promotes genome stability upon replication stress in vivo. The data suggest combined influences of the Mre11 complex on DNA repair, as well as the responses to DNA damage and DNA replication stress. IMPLICATIONS: A novel mouse model was developed, by combining a vav(cre)-inducible ATM knockout mouse with an NBS1 hypomorphic mutation, to analyze ATM-independent functions of the Mre11 complex in vivo. These data show that the DNA repair, rather than DDR signaling functions of the complex, is acutely required in the context of ATM deficiency to suppress genome instability and lymphomagenesis. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26538284      PMCID: PMC4755792          DOI: 10.1158/1541-7786.MCR-15-0281

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  50 in total

1.  Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance.

Authors:  Eric J Brown; David Baltimore
Journal:  Genes Dev       Date:  2003-03-01       Impact factor: 11.361

2.  ATR regulates fragile site stability.

Authors:  Anne M Casper; Paul Nghiem; Martin F Arlt; Thomas W Glover
Journal:  Cell       Date:  2002-12-13       Impact factor: 41.582

3.  Switch junction sequences in PMS2-deficient mice reveal a microhomology-mediated mechanism of Ig class switch recombination.

Authors:  M R Ehrenstein; C Rada; A M Jones; C Milstein; M S Neuberger
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

4.  Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors.

Authors:  Carlos Lois; Elizabeth J Hong; Shirley Pease; Eric J Brown; David Baltimore
Journal:  Science       Date:  2002-01-10       Impact factor: 47.728

5.  ATR disruption leads to chromosomal fragmentation and early embryonic lethality.

Authors:  E J Brown; D Baltimore
Journal:  Genes Dev       Date:  2000-02-15       Impact factor: 11.361

6.  A murine model of Nijmegen breakage syndrome.

Authors:  Bret R Williams; Olga K Mirzoeva; William F Morgan; Junyu Lin; Wesley Dunnick; John H J Petrini
Journal:  Curr Biol       Date:  2002-04-16       Impact factor: 10.834

7.  The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1.

Authors:  Kurt A Krummel; Stacy R Denison; Eric Calhoun; Leslie A Phillips; David I Smith
Journal:  Genes Chromosomes Cancer       Date:  2002-06       Impact factor: 5.006

Review 8.  ATM and related protein kinases: safeguarding genome integrity.

Authors:  Yosef Shiloh
Journal:  Nat Rev Cancer       Date:  2003-03       Impact factor: 60.716

9.  Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.

Authors:  Hikmat Al-Ahmadie; Gopa Iyer; Marcel Hohl; Saurabh Asthana; Akiko Inagaki; Nikolaus Schultz; Aphrothiti J Hanrahan; Sasinya N Scott; A Rose Brannon; Gregory C McDermott; Mono Pirun; Irina Ostrovnaya; Philip Kim; Nicholas D Socci; Agnes Viale; Gary K Schwartz; Victor Reuter; Bernard H Bochner; Jonathan E Rosenberg; Dean F Bajorin; Michael F Berger; John H J Petrini; David B Solit; Barry S Taylor
Journal:  Cancer Discov       Date:  2014-06-16       Impact factor: 39.397

10.  Transcription-targeted DNA deamination by the AID antibody diversification enzyme.

Authors:  Jayanta Chaudhuri; Ming Tian; Chan Khuong; Katrin Chua; Eric Pinaud; Frederick W Alt
Journal:  Nature       Date:  2003-04-09       Impact factor: 49.962

View more
  5 in total

1.  The Mre11-Nbs1 Interface Is Essential for Viability and Tumor Suppression.

Authors:  Jun Hyun Kim; Malgorzata Grosbart; Roopesh Anand; Claire Wyman; Petr Cejka; John H J Petrini
Journal:  Cell Rep       Date:  2017-01-10       Impact factor: 9.423

2.  A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability.

Authors:  Katerina D Fagan-Solis; Dennis A Simpson; Rashmi J Kumar; Luciano G Martelotto; Lisle E Mose; Naim U Rashid; Alice Y Ho; Simon N Powell; Y Hannah Wen; Joel S Parker; Jorge S Reis-Filho; John H J Petrini; Gaorav P Gupta
Journal:  Cell Rep       Date:  2020-02-04       Impact factor: 9.423

3.  There and Back Again: The Middle Earth of DNA Repair.

Authors:  Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2016-10       Impact factor: 5.852

4.  Deficient Activity of the Nuclease MRE11A Induces T Cell Aging and Promotes Arthritogenic Effector Functions in Patients with Rheumatoid Arthritis.

Authors:  Yinyin Li; Yi Shen; Philipp Hohensinner; Jihang Ju; Zhenke Wen; Stuart B Goodman; Hui Zhang; Jörg J Goronzy; Cornelia M Weyand
Journal:  Immunity       Date:  2016-10-11       Impact factor: 31.745

5.  Nbn-Mre11 interaction is required for tumor suppression and genomic integrity.

Authors:  Jun Hyun Kim; Alexander V Penson; Barry S Taylor; John H J Petrini
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-08       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.